(Q38391528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Adoptive cellular therapy: a race to the finish line (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Stanley R Riddell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

3 March 2020

language of work or name

English

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

280ps7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

publication type of scholarly work

3 March 2020

review article

1 reference

Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Genetic therapies against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Oncology Meets Immunology: The Cancer-Immunity Cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Transgenic mice with a diverse human T cell antigen receptor repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

T-cell immunotherapy: looking forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Deconstructing the Peptide-MHC Specificity of T Cell Recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Leukemia following chemotherapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Naive and memory CD4+ T cell survival controlled by clonal abundance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

A guide to genome engineering with programmable nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

In vivo discovery of immunotherapy targets in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Lineage relationship of effector and memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Heterogeneous differentiation patterns of individual CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Disparate individual fates compose robust CD8+ T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAA3643

10.1126/SCITRANSLMED.AAA3643

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25810311%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference